Danaher Corporation $DHR Shares Bought by Turtle Creek Wealth Advisors LLC

Turtle Creek Wealth Advisors LLC raised its holdings in shares of Danaher Corporation (NYSE:DHR) by 348.2% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 13,689 shares of the conglomerate’s stock after acquiring an additional 10,635 shares during the period. Turtle Creek Wealth Advisors LLC’s holdings in Danaher were worth $3,033,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the business. EP Wealth Advisors LLC bought a new stake in Danaher during the second quarter worth about $3,807,000. Puzo Michael J bought a new position in shares of Danaher during the 2nd quarter valued at about $8,624,000. Madison Asset Management LLC bought a new position in shares of Danaher during the 2nd quarter valued at about $85,451,000. First Nebraska Trust Co purchased a new position in shares of Danaher during the 2nd quarter valued at about $14,106,000. Finally, Colton Groome Financial Advisors LLC purchased a new position in shares of Danaher during the 3rd quarter valued at about $592,000. 79.05% of the stock is currently owned by institutional investors.

Danaher News Roundup

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Strategic NVIDIA collaboration: Danaher and NVIDIA are combining NVIDIA’s accelerated-computing and AI technologies with Danaher’s scientific instruments, laboratory automation, workflow software and life-sciences expertise. The initiative is intended to advance autonomous science and accelerate drug discovery and other laboratory research, potentially supporting long-term growth in Danaher’s life-sciences businesses. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: AI-powered laboratory expansion: Danaher reportedly plans to launch its first AI-powered autonomous laboratory, with commercial-scale operations targeted for early 2027. Although the announcement had limited immediate market impact, it reinforces the company’s positioning in laboratory automation and AI-enabled scientific workflows. How to Invest in AI Drug Discovery
• Positive Sentiment: Potential earnings beat: Zacks reports that Danaher has a strong earnings-surprise history and currently has favorable Earnings ESP and consensus-estimate factors for its next quarterly report. Analysts expect earnings growth, which may support sentiment ahead of the results. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Upcoming earnings remain the key catalyst: Danaher is projected to announce quarterly results on Wednesday. The current reports point to a possible beat, but they do not provide new reported financial results; the stock’s next move will depend on actual revenue, earnings and forward guidance. Danaher Projected to Announce Earnings

Analysts Set New Price Targets

Several analysts have issued reports on the company. Barclays upped their target price on Danaher from $230.00 to $255.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. Wall Street Zen raised shares of Danaher from a “hold” rating to a “buy” rating in a research note on Saturday, October 10th. Royal Bank Of Canada boosted their price objective on shares of Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a report on Monday, October 5th. UBS Group began coverage on shares of Danaher in a research note on Wednesday, September 9th. They issued a “buy” rating and a $250.00 price objective for the company. Finally, Evercore reaffirmed an “outperform” rating and set a $230.00 target price on shares of Danaher in a report on Monday, July 6th. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $235.41.

Danaher Trading Up 3.0%

NYSE:DHR traded up $6.83 during midday trading on Thursday, reaching $231.52. 2,554,761 shares of the stock traded hands, compared to its average volume of 4,447,386. The stock has a market capitalization of $162.76 billion, a P/E ratio of 41.12, a PEG ratio of 2.80 and a beta of 0.76. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. The company has a fifty day moving average of $212.92 and a 200 day moving average of $195.39. Danaher Corporation has a 12 month low of $160.93 and a 12 month high of $242.80.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. During the same quarter last year, the firm earned $0.77 EPS. The company’s revenue was up 5.5% on a year-over-year basis. On average, research analysts predict that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Wednesday, September 30th. Danaher’s dividend payout ratio is currently 28.42%.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.